Evidence map›Paper›PMID 28852052›Full record

ArticleScientific reports2017

TGF-β participates choroid neovascularization through Smad2/3-VEGF/TNF-α signaling in mice with Laser-induced wet age-related macular degeneration.

Xiaolei Wang, Wei Ma, Song Han, Zhaoyang Meng, Lu Zhao, Yi Yin, Yanling Wang, Junfa Li

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Rac1 overexpression promotes Treg-derived cytokines to mediate choroidal neovascularization in wet age-related macular degeneration.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease.The Journal of pharmacology and experimental therapeutics · 2023
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiaolei WangDepartment of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, PR China. wangxleye@ccmu.edu.cn.
Wei MaDepartment of Neurobiology and Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, PR China.
Song HanDepartment of Neurobiology and Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, PR China.
Zhaoyang MengDepartment of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, PR China.
Lu ZhaoDepartment of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, PR China.
Yi YinDepartment of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, PR China.
Yanling WangDepartment of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, PR China.
Junfa LiDepartment of Neurobiology and Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, PR China. junfali@ccmu.edu.cn.
Capital Medical University · CNBeijing Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Choroidal neovascularization(CNV) is the most severe complication in Age-related macular degeneration(AMD) and the most common cause of irreversible blindness in the elderly in developed world. The aim of this study was to identify the effect of transforming growth factor-β(TGF-β) and Smad2/3-VEGF/TNF-α signaling on CNV angiopoiesis, and to explore TGF-β inhibitors on the development of CNV in a CNV mouse model. Fundus fluorescein angiography(FFA) was used to evaluate the laser-induced CNV formation. The histology of CNV lesions stained with hematoxylin-eosin(HE) was obtained. The immunofluorescent staining was performed to determine TGF-β protein expression. The expressions of TGF-β, phosphorylated Smad2/3, VEGF and TNF-α were determined by using Western blot analysis. The CNV areas were analyzed by using fluorescein stain on RPE/choroid-sclera flat mounts. We found the levels of TGF-β protein expression increasingly reached the peak till 3rd week during the CNV development. The protein levels of VEGF and TNF-α also increased significantly in CNV mice, which were inhibited by a synthetic TGF-β inhibitor LY2157299 or a natural TGF-β inhibitor Decorin. The phosphorylated Smad2/3 levels increased significantly in CNV mice, but this response was profoundly suppressed by the TGF-β inhibitors. Here we have demonstrated that TGF-β/Smad signaling plays an important role in Laser-induced CNV formation through down-regulation of VEGF and TNF-α expressions, suggesting TGF-β inhibitors may provide an alternative to traditional methods in wet AMD treatment.

Indexed as

AnimalsBlotting, WesternChoroidal NeovascularizationDisease Models, AnimalFluorescein AngiographyHistocytochemistryLasersMacular DegenerationMiceMicroscopy, FluorescenceSignal TransductionSmad2 ProteinSmad3 ProteinTransforming Growth Factor betaTumor Necrosis Factor-alphaVascular Endothelial Growth Factor ASmad2 ProteinSmad2 protein, mouseSmad3 ProteinSmad3 protein, mouseTransforming Growth Factor betaTumor Necrosis Factor-alphaVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouse

Identifiers

PMID28852052
PMCPMC5575286
OpenAlexW2749812557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.